Previous 10 | Next 10 |
Preliminary Amarin (NASDAQ: AMRN ) Q1 numbers show revenue of about $150M vs. estimates for roughly $130M. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
April 9, 2020 Palm Beach, FL – April 9, 2020 – Recent industry reports on the projected growth of the global dermatologicals markets predict a continued surge in revenues. A report from Allied Market Research said that the global dermatologicals market is expected to...
Amarin (NASDAQ: AMRN ) will host a conference call on Monday, April 13, at 4:30 pm ET to provide preliminary Q1 results and to update on its operations, including its planned appeal of the adverse patent related to Vascepa (icosapent ethyl). More news on: Amarin Corporation plc, Healthca...
DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with management on Monday, April 13, 2020, at 4:30 p.m. ET to discuss the company's preliminary first quarter 2020 financial res...
Shares of the Irish biopharma Amarin Corp. (NASDAQ: AMRN) rose by as much as 11.9% in early action Wednesday morning. While the company didn't release any news that would spark this double-digit rally today, Amarin's shares have been gaining favor among a number of Wall Street analysts and b...
Amarin, Corp ( AMRN ) has been an extremely turbulent and highly visible stock over the years, with investors making and losing fortunes on the volatility generated by the interim successes and failures of the company's cardiovascular therapy, Vascepa . To be sure, this drug developer has succ...
4 Penny Stocks To Watch At The Start Of The Week This week is a short one but penny stocks are already off to a wild start. During premarket trading, headlines were flying and this time it wasn’t all about coronavirus. That is, at least, from a medical perspective. The pandemic has ca...
Amarin (NASDAQ: AMRN) lost a staggering 72.7% of its value in March, according to data from S&P Global Market Intelligence . The drugmaker's shares collapsed late in the month following an adverse patent ruling for its prescription omega-3 treatment, Vascepa. This somew...
On Monday, March 30, a district court judge in Nevada ruled in favor of two generic drug companies seeking to invalidate patents covering Vascepa, a fish oil product developed and marketed by Amarin (NASDAQ: AMRN) . Investors witnessed $3.3 billion in valuation go up in smoke as the stock plu...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...